Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ANABNASDAQ:HCMNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$24.40-3.7%$22.70$16.50▼$26.55$2.13BN/A59,959 shs16,331 shsANABAnaptysBio$22.45-0.5%$19.73$12.21▼$41.31$653.12M-0.2611,541 shs683,007 shsHCMHUTCHMED$13.77-0.6%$14.08$11.51▼$21.50$2.42B0.55100,582 shs87,577 shsXENEXenon Pharmaceuticals$28.72-1.1%$33.00$26.74▼$46.00$2.20B1.21540,340 shs2.46 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%-7.85%-4.24%+30.69%+2,439,999,900.00%ANABAnaptysBio0.00%+9.83%+5.95%+53.35%-6.22%HCMHUTCHMED0.00%+2.76%-8.20%-13.45%-25.69%XENEXenon Pharmaceuticals0.00%-3.46%-24.97%-19.75%-24.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AANABAnaptysBio2.7733 of 5 stars4.41.00.00.02.81.70.6HCMHUTCHMED1.9891 of 5 stars3.02.00.00.02.20.01.9XENEXenon Pharmaceuticals3.5552 of 5 stars4.54.00.00.03.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AANABAnaptysBio 2.70Moderate Buy$40.3879.84% UpsideHCMHUTCHMED 2.00Hold$19.0037.98% UpsideXENEXenon Pharmaceuticals 3.00Buy$54.8290.87% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, HCM, AAPG, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $55.005/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.17N/AN/AN/A∞ANABAnaptysBio$111.87M5.90N/AN/A$3.32 per share6.76HCMHUTCHMED$630.20M3.81$0.56 per share24.51$4.27 per share3.22XENEXenon Pharmaceuticals$7.50M293.84N/AN/A$14.18 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.43N/AN/AN/AN/A6/18/2025 (Estimated)XENEXenon Pharmaceuticals-$182.39M-$3.23N/AN/AN/AN/A-24.69%-23.68%8/14/2025 (Estimated)Latest ANAB, HCM, AAPG, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AANABAnaptysBioN/A10.2310.23HCMHUTCHMED0.072.812.68XENEXenon PharmaceuticalsN/A22.2122.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AANABAnaptysBioN/AHCMHUTCHMED8.82%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AANABAnaptysBio33.50%HCMHUTCHMED3.60%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.11 millionN/AN/AANABAnaptysBio10029.38 million20.17 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableXENEXenon Pharmaceuticals21076.73 million72.03 millionOptionableANAB, HCM, AAPG, and XENE HeadlinesRecent News About These CompaniesUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)June 2 at 4:23 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DEMay 31 at 3:14 AM | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30 at 4:01 PM | globenewswire.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)May 30 at 2:31 AM | marketbeat.comAmeriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 28, 2025 | marketbeat.comWoodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 27, 2025 | marketbeat.comTwo Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 27, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLCMay 26, 2025 | marketbeat.comNorthern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 26, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LPMay 25, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.comMay 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesMay 23, 2025 | marketbeat.comFair Value analysis proves accurate as XENE drops 37% from February 2024 peakMay 21, 2025 | investing.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LPMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 21, 2025 | marketbeat.comEnsign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 19, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for XENE EarningsMay 18, 2025 | marketbeat.comSphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 17, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for XENE EarningsMay 17, 2025 | marketbeat.comTraders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, HCM, AAPG, and XENE Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$24.40 -0.95 (-3.75%) As of 05/30/2025 02:44 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.AnaptysBio NASDAQ:ANAB$22.45 -0.11 (-0.49%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$22.23 -0.22 (-0.98%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.HUTCHMED NASDAQ:HCM$13.77 -0.09 (-0.65%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$13.89 +0.12 (+0.87%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Xenon Pharmaceuticals NASDAQ:XENE$28.72 -0.32 (-1.10%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$28.85 +0.13 (+0.45%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
